| P2093 | author name string | Peter A McCullough | |
| | Varun Agrawal | |
| | Mohit Agarwal | |
| | Victor Marinescu | |
| P2860 | cites work | Statin induced proteinuria: renal injury or renoprotection? | Q80512696 |
| | Double-blind, placebo-controlled study on the effect of the aldosterone receptor antagonist spironolactone in patients who have persistent proteinuria and are on long-term angiotensin-converting enzyme inhibitor therapy, with or without an angiotens | Q80796915 |
| | CDC/AHA Workshop on Markers of Inflammation and Cardiovascular Disease: Application to Clinical and Public Health Practice: report from the laboratory science discussion group | Q81178841 |
| | Glomerular disease related to anti-VEGF therapy | Q81441190 |
| | Gross proteinuria is a strong risk predictor for cardiovascular mortality in Brazilian type 2 diabetic patients | Q81976625 |
| | Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes | Q28188162 |
| | Chronic kidney disease and mortality risk: a systematic review | Q28243131 |
| | Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization | Q28283679 |
| | K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification | Q29547560 |
| | Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy | Q29615215 |
| | Role of oxidative modifications in atherosclerosis | Q29617974 |
| | Effects of statins in patients with chronic kidney disease: meta-analysis and meta-regression of randomised controlled trials | Q30841365 |
| | Combination therapy with an angiotensin receptor blocker and an ACE inhibitor in proteinuric renal disease: a systematic review of the efficacy and safety data. | Q31046296 |
| | Evidence of transcellular permeability pathway in microvessels | Q31853436 |
| | Telmisartan, ramipril, or both in patients at high risk for vascular events | Q33156143 |
| | Albuminuria and renal insufficiency prevalence guides population screening: results from the NHANES III. | Q33959305 |
| | The effect of proteinuria on relative mortality in type 1 (insulin-dependent) diabetes mellitus | Q34200394 |
| | Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Preventi | Q34272627 |
| | Leptin and renal disease | Q34482861 |
| | Effects of an ACE inhibitor/calcium antagonist combination on proteinuria in diabetic nephropathy | Q34753900 |
| | Lipoprotein management in patients with cardiometabolic risk: consensus statement from the American Diabetes Association and the American College of Cardiology Foundation | Q34765654 |
| | Coronary artery calcification scores in patients with chronic kidney disease prior to dialysis: reliability as a trial outcome measure | Q35025394 |
| | Proteinuria: how to evaluate an important finding | Q35163370 |
| | Effect of proteinuria and glomerular filtration rate on cardiovascular risk in essential hypertension | Q35918670 |
| | Predictors of cardiovascular events in patients with type 2 diabetic nephropathy and hypertension: a case for albuminuria | Q35918674 |
| | Chronic renal failure: a cardiovascular risk factor | Q36335324 |
| | Lysophosphatidylcholine and secretory phospholipase A2 in vascular disease: mediators of endothelial dysfunction and atherosclerosis | Q36348728 |
| | Effects of low dose ramipril on cardiovascular and renal outcomes in patients with type 2 diabetes and raised excretion of urinary albumin: randomised, double blind, placebo controlled trial (the DIABHYCAR study). | Q36456306 |
| | A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer | Q36509678 |
| | How does proteinuria cause progressive renal damage? | Q36621209 |
| | ADMA levels correlate with proteinuria, secondary amyloidosis, and endothelial dysfunction. | Q36677348 |
| | Risks of proteinuria and hypertension with bevacizumab, an antibody against vascular endothelial growth factor: systematic review and meta-analysis | Q36721468 |
| | Testing for chronic kidney disease: a position statement from the National Kidney Foundation | Q36894958 |
| | Microalbuminuria and cardiovascular disease | Q36910612 |
| | Incidence and risk factors for stroke in American Indians: the Strong Heart Study | Q37368441 |
| | Macro-microangiopathy and endothelial dysfunction in NIDDM patients with and without diabetic nephropathy | Q39437715 |
| | Increased pulse wave velocity is associated with low creatinine clearance and proteinuria in a screened cohort | Q40331970 |
| | Coronary artery calcification is related to coronary atherosclerosis in chronic renal disease patients: a study comparing EBCT-generated coronary artery calcium scores and coronary angiography | Q40501382 |
| | Transport of macromolecules through microvascular walls | Q41208119 |
| | Salt intake and reductions in arterial pressure and proteinuria. Is there a direct link? | Q41270846 |
| | Atherosclerosis and the two faces of endothelial nitric oxide synthase | Q41690339 |
| | Cytoskeletal rearrangement mediates human microvascular endothelial tight junction modulation by cytokines | Q42442374 |
| | Familial aggregation of coronary artery calcium in families with type 2 diabetes | Q43566169 |
| | The prognostic significance of proteinuria: the Framingham study | Q43852381 |
| | Competing risk factor analysis of end-stage renal disease and mortality in chronic kidney disease | Q43888780 |
| | Increased urinary albumin excretion, endothelial dysfunction, and chronic low-grade inflammation in type 2 diabetes: progressive, interrelated, and independently associated with risk of death | Q43935480 |
| | Effect of pravastatin on proteinuria in patients with well-controlled hypertension | Q44053702 |
| | A controlled, prospective study of the effects of atorvastatin on proteinuria and progression of kidney disease. | Q44338046 |
| | Endothelial dysfunction and inflammation in asymptomatic proteinuria. | Q44358537 |
| | Glomerular filtration rate, albuminuria, and risk of cardiovascular and all-cause mortality in the US population | Q44513905 |
| | Proteinuria and risk for stroke and coronary heart disease during 27 years of follow-up: the Honolulu Heart Program | Q44970745 |
| | Effect of angiotensin-converting enzyme inhibition on survival in 3773 Chinese type 2 diabetic patients | Q44975136 |
| | Albuminuria, a therapeutic target for cardiovascular protection in type 2 diabetic patients with nephropathy | Q45012594 |
| | Prevalence of hypertension in renal disease | Q45020640 |
| | A prospective study of microalbuminuria and incident coronary heart disease and its prognostic significance in a British population: the EPIC-Norfolk study | Q45150538 |
| | Low-protein diet for diabetic nephropathy: a meta-analysis of randomized controlled trials | Q45897743 |
| | Determinants of coronary artery calcification in diabetics with and without nephropathy. | Q46008035 |
| | Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. | Q46426098 |
| | Aliskiren combined with losartan in type 2 diabetes and nephropathy | Q46558669 |
| | Effect of fenofibrate on kidney function: a 6-week randomized crossover trial in healthy people | Q46576858 |
| | Add-on and withdrawal effect of pravastatin on proteinuria in hypertensive patients treated with AT receptor blockers | Q46598175 |
| | Triple pharmacological blockade of the renin-angiotensin-aldosterone system in nondiabetic CKD: an open-label crossover randomized controlled trial. | Q46635485 |
| | Albuminuria and incident coronary heart disease in Australian Aboriginal people | Q46654222 |
| | Long-term renoprotective effects of standard versus high doses of telmisartan in hypertensive nondiabetic nephropathies | Q46822599 |
| | Beneficial impact of spironolactone in diabetic nephropathy | Q46826573 |
| | The relationships of proteinuria, serum creatinine, glomerular filtration rate with cardiovascular disease mortality in Japanese general population | Q46963308 |
| | Association between circulating monocyte chemoattractant protein-1 and urinary albumin excretion in nonobese Type 2 diabetic patients | Q46966140 |
| | Correlates of systolic hypertension in patients with chronic kidney disease | Q48539717 |
| | Screening for proteinuria in US adults: a cost-effectiveness analysis. | Q50735258 |
| | Efficacy and variability of the antiproteinuric effect of ACE inhibition by lisinopril. | Q54348402 |
| | Association of albuminuria with systolic and diastolic left ventricular dysfunction in type 2 diabetes: the Strong Heart Study | Q57218466 |
| | Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy | Q57704237 |
| | Proteinuria as a risk factor for cardiovascular disease and mortality in older people: a prospective study | Q57740575 |
| | Proteinuria and interstitial injury | Q57741376 |
| | Hypoalbuminemia increases lysophosphatidylcholine in low-density lipoprotein of normocholesterolemic subjects | Q57791049 |
| | Vascular function in the forearm of hypercholesterolaemic patients off and on lipid-lowering medication | Q57791545 |
| | EFFECTS OF SIMVASTATIN AND CHOLESTYRAMINE ON LIPOPROTEIN PROFILE IN HYPERLIPIDAEMIA OF NEPHROTIC SYNDROME | Q57791799 |
| | ADMA, proteinuria, and insulin resistance in non-diabetic stage I chronic kidney disease | Q58949457 |
| | Plasma lipoproteins and renal function during simvastatin treatment in diabetic nephropathy | Q60218020 |
| | Urinary Albumin Excretion Predicts Cardiovascular and Noncardiovascular Mortality in General Population | Q61965156 |
| | Glomerular and hormonal responses to dietary protein intake in human renal disease | Q69014924 |
| | Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. The Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group | Q70989850 |
| | Effects of sodium intake on albumin excretion in patients with diabetic nephropathy treated with long-acting calcium antagonists | Q71208893 |
| | Proteinuria predicts stroke and other atherosclerotic vascular disease events in nondiabetic and non-insulin-dependent diabetic subjects | Q71739880 |
| | Hemorheology, plasma protein composition and von Willebrand factor in type I diabetic nephropathy | Q71752285 |
| | The increased risk of coronary heart disease associated with nephrotic syndrome | Q72581796 |
| | Simvastatin therapy for hypercholesterolemic patients with nephrotic syndrome or significant proteinuria | Q72664928 |
| | Plasma prekallikrein: a risk marker for hypertension and nephropathy in type 1 diabetes | Q73321686 |
| | Albuminuria is directly associated with increased plasma PAI-1 and factor VII levels in NIDDM patients | Q73425316 |
| | Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia) | Q73499190 |
| | The risk of cardiovascular disease mortality associated with microalbuminuria and gross proteinuria in persons with older-onset diabetes mellitus | Q73733629 |
| | Coronary calcium in adults with type 1 diabetes: a stronger correlate of clinical coronary artery disease in men than in women | Q74256386 |
| | The blunting of the antiproteinuric efficacy of ACE inhibition by high sodium intake can be restored by hydrochlorothiazide | Q74816907 |
| | Hyperlipidemia in patients with chronic renal disease | Q77573739 |
| | Rising tide of cardiovascular disease in American Indians. The Strong Heart Study | Q77726057 |
| | Long-term effects of spironolactone on proteinuria and kidney function in patients with chronic kidney disease | Q79226809 |
| | Proteinuria as a significant determinant of hypertension in a normotensive screened cohort in Okinawa, Japan | Q79649263 |
| | Effect of a very low-protein diet on outcomes: long-term follow-up of the Modification of Diet in Renal Disease (MDRD) Study | Q79702558 |
| | Longitudinal follow-up and outcomes among a population with chronic kidney disease in a large managed care organization | Q79811373 |
| | Kidney dysfunction as a risk factor for first symptomatic stroke events in a general Japanese population--the Ohasama study | Q80065099 |
| | Macroalbuminuria is a better risk marker than low estimated GFR to identify individuals at risk for accelerated GFR loss in population screening | Q80087723 |
| | Renoprotection of Optimal Antiproteinuric Doses (ROAD) Study: a randomized controlled study of benazepril and losartan in chronic renal insufficiency | Q80313261 |
| P433 | issue | 4 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | circulatory system | Q11068 |
| P304 | page(s) | 301-311 | |
| P577 | publication date | 2009-04-01 | |
| P1433 | published in | Nature Reviews Cardiology | Q2108444 |
| P1476 | title | Cardiovascular implications of proteinuria: an indicator of chronic kidney disease | |
| P478 | volume | 6 | |